8-K current report · filed Nov 16, 2026

Bruker Corp (BRKR) 8-K Current Report: November 16, 2026

Item 5.02Item 8.01Item EX-99.1BRKR overview

Short answer

Bruker Corp (BRKR) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Board expansion from 11 to 12 directors, increasing governance capacity.

Bruker Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expansion from 11 to 12 directors, increasing governance capacity
  • Eicke Latz MD PhD joins effective January 1, 2027, serving Class II through the 2029 Annual Meeting
  • Standard non-employee director compensation, with no disclosed related-party transaction
  • Committee assignments pending, limiting near-term visibility into his oversight responsibilities

Item 8.01 · Other Events

  • Quarterly cash dividend: $0.05 per common share
  • Payable January 7, 2027, to shareholders of record December 21, 2026
  • Dividend declaration signals continued shareholder-return commitment by Bruker’s board

Item EX-99.1 · Exhibit EX-99.1

  • Dr. Eicke Latz joining Bruker’s board effective January 1, 2027
  • Scientific leadership in innate immunity, inflammation, proteomics, and molecular diagnostics
  • Co-founder of five biotechnology companies, including IFM Therapeutics and Odyssey Therapeutics
  • Board appointment strengthens Bruker’s biopharma, disease-biology, and drug-discovery expertise

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bruker Corp 8-K filings

Get the next BRKR 8-K as it lands

Follow BRKR for push alerts, or ask the research agent what this filing means.